Objective: To explore the effectiveness and safety of integrated traditional Chinese and western medicine in the treatment of MCI patients. Methods: Search three English databases, four Chinese databases, and assess the risk of bias according to Cochrane tools. Statistics will be used for heterogeneity assessment, sensitivity analysis, data synthesis, funnel chart generation and subgroup analysis. If a sufficiently uniform study is found, a meta-analysis will be performed and any differences will be described in groups. Results: A total of 15 studies were included, 11 studies treated MMSE as an outcome indicator, 7 studies used MoCA as an outcome indicator, 6 studies reported overall effectiveness, 3 studies used ADL as an outcome indicator, and 2 studies reported blood The data of markers and the results of 15 studies are beneficial to the traditional Chinese medicine combined with western medicine group. Conclusion: The conclusion shows that the treatment of mild cognitive impairment with integrated traditional Chinese and western medicine is superior to the single use of traditional Chinese medicine or western medicine in improving MMSE, MoCA, ADL, total effective rate score and reducing blood markers Aβ and IT-6, and the incidence of adverse reactions Lower, higher safety, for clinical reference. However, there are flaws in the research methodology, which need to be confirmed by more high-quality literature.

Wang Wei, Diwu Yongchang, Yang Qian, Wang Dengkun, Gou Yurui. Systematic Evaluation of the Efficacy of Integrated Traditional Chinese and Western Medicine in Treating Mild Cognitive Impairment. International Journal of Frontiers in Medicine (2021), Vol. 3, Issue 1: 67-76. https://doi.org/10.25236/IJFM.2021.030113.

[1] Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227-2234.

[2] Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80(11):1048-1056.

[3] Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3) :126-135.

[4] Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62(7):1160-1167.

[5] Dong L, Hyde AJ, Zhang AL, Xue CC, May BH. Chinese Herbal Medicine for Mild Cognitive Impairment Using Montreal Cognitive Assessment: A Systematic Review. J Altern Complement Med. 2019; 25(6):578-592.

[6] Dong L, May BH, Feng M, et al. Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes. Phytother Res. 2016;30(10):1592-1604.

[7]Y ang Zhaojun, Miaser, Chen Hongxia. Research progress in the treatment of mild cognitive impairment with integrated traditional Chinese and western medicine[in Chinese]. Journal of Practical Traditional Chinese Internal Medicine, 2020, 34(09): 67-71.

[8] Petersen RC, Smith GE, Waring SC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56(3):303Y308.

[9] Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256(3): 183Y194.

[10] Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology . Neurology 2018; 90:126–35

[11]A lbert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7 (3):270-279.

[12] American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. Washington, DC: American Psychiatric Publishing, 2013.

[13] Batistela MS, Josviak ND, Sulzbach CD, de Souza RL. An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases. Int J Neurosci. 2017; 127(6):547-558.

[14] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. Published 2015 Jan 1 .

[15] Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. (2019-07) http://www.training. cochrance.org /handbook.

[16] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. Published 2011 Oct 18.

[17] Yang Jiajun, Tian Qiaoxian, Sun Xiaojiang. Efficacy of Allison combined with Wuling Capsule in the treatment of mild cognitive impairment[in Chinese]. Chinese Journal of Gerontology, 2011, 31(20): 3886-3888.

[18] Zheng Weili, Zhang Wen. Clinical study of Buqimaitong tablets in the treatment of mild cognitive dysfunction [in Chinese]. Electronic Journal of Clinical Medicine Literature, 2016, 3(30): 5927-5928.

[19] Xie Liying, Chen Chaojun. Buyang Huanwu Decoction combined with donepezil in the treatment of 30 cases of mild cognitive impairment [in Chinese]. Jiangxi Traditional Chinese Medicine, 2015, 46(04): 26-28.

[20] Yu Ye. Analysis of the clinical effect of Buyang Huanwu Decoction combined with donepezil in the treatment of mild cognitive dysfunction[in Chinese]. Everyone Health (Academic Edition), 2016, 10(08): 59-60.

[21] Liu Xiaorui. Clinical observation of Buyang Huanwu Decoction combined with donepezil in the treatment of mild cognitive dysfunction[in Chinese]. Journal of Practical Traditional Chinese Medicine, 2020, 36(03): 359-360.

[22] Wu Jie, Wang Yu. Analysis of the effect of Guyuan Xingnao Decoction combined with Oxiracetam in the treatment of mild cognitive dysfunction[in Chinese]. Shanxi Medical Journal, 2019, 48(10): 1207-1210.

[23] Yang Cheng, Zhu Caifeng, Liu Lili. Analysis of the effect of Guyuan Xingnao Decoction combined with Oxiracetam in the treatment of mild cognitive dysfunction[in Chinese]. World Traditional Chinese Medicine, 2015, 10(06): 842-844+848.

[24] Yu Milin. Observation on the efficacy of galantamine combined with Yindan Xinnaotong Soft Capsule in the treatment of mild cognitive dysfunction[in Chinese]. Journal of Integrated Traditional Chinese and Western Medicine Cardio-Cerebrovascular Disease, 2012, 10(09): 1077-1079 .

[25]Wu Yuanhua, Shao Yong, Zhu Guangqi, Cao Liping, Cai Jing. Treatment of 23 cases of cognitive dysfunction in young and old with traditional Chinese medicine for clearing brain, nourishing marrow and nourishing blood combined with low-dose huperzine A[in Chinese]. Chinese Journal of Experimental Prescriptions, 2013, 19(03):298-300.

[26] Wang Zhuoer. Observation on 26 Cases of Mild Cognitive Impairment Treated by Integrated Traditional Chinese and Western Medicine [in Chinese]. Zhejiang Journal of Traditional Chinese Medicine, 2012, 47(04): 288.

[27] He Jianhua, Jiang Xuanguang, Wu Zongming, Zhang Jiande. Self-made Huannao Yicong Decoction combined with Western medicine in the treatment of cognitive impairment in the elderly and young and its effect on the hemorheology of patients[in Chinese]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2017, 26(18):1989-1991.

[28] Hu Ke, Zhang Baochao, Jia Dongpei. Jiannao Bushen Pills combined with Ginkgo biloba leaves in the treatment of mild cognitive dysfunction [in Chinese]. Chinese Journal of Experimental Formulas, 2015, 21(23): 160-163.

[29] Liu Yan, Huang Xiaobo, Wei Cuibai, Wang Ningqun, Chen Yujing, Wu Xiling. A clinical study of Naokang Ⅱ combined with aniracetam capsules in the treatment of elderly amnestic mild cognitive impairment [in Chinese]. Chinese Journal of Information on Traditional Chinese Medicine, 2020, 27(08):30-35.

[30] Wang Xiaoyan. Clinical observation on the treatment of mild cognitive impairment with integrated traditional Chinese and western medicine[in Chinese]. Chinese Medical Guide, 2010, 8(35): 269-270.

[31] Xuan Hongwei. Clinical observation on the treatment of mild cognitive impairment with integrated traditional Chinese and western medicine[in Chinese]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2017, 27(20): 33-34.

[32] Kasper S, Bancher C, Eckert A, et al. Management of mild cognitive impairment (MCI): The need for national and international guidelines [published online ahead of print, 2020 Feb 5]. World J Biol Psychiatry. 2020; 1-16.